ArticlePloS one2009

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Clara I Aceves-Luquero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.